All Posts
New analysis does not support a major role of school reopening in the second COVID-19 wave in Israel
26 Jan, 2021 | 00:52h | UTC
Commentary on Twitter
Very interesting paper
Despite previous certainty about schools being the driving factor in the second wave in Israel, now looks unlikely
Easing restrictions of large gatherings in adults the predominant factor
Young adults, not children, as elsewherehttps://t.co/oWHbZynRpL
— Alasdair Munro (@apsmunro) January 25, 2021
UNICEF Executive Director Statement: “Children cannot afford another year of school disruption”
26 Jan, 2021 | 00:53h | UTCChildren cannot afford another year of school disruption – UNICEF
Commentary on Twitter
"Children cannot afford another year of school disruption."
Statement by UNICEF Executive Director @unicefchief Henrietta H. Fore
Find out more 👉https://t.co/DwuaHGub3B pic.twitter.com/jQbdLK2EE5
— UNICEF Rwanda (@unicefrw) January 13, 2021
German study provides evidence that opening schools may be safe
26 Jan, 2021 | 00:51h | UTCGerman Study Provides Evidence that Opening Schools May Be Safe – Physician’s Weekly
Original Study: Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany – JAMA Pediatrics
Editorial: To Spread or Not to Spread SARS-CoV-2—Is That the Question?
Related: Three studies highlight low COVID risk of in-person school
WHO COVAX Announces new agreement, plans for first deliveries
26 Jan, 2021 | 00:49h | UTCCOVAX Announces new agreement, plans for first deliveries – World Health Organization
Commentary on Twitter
#COVAX has signed an agreement with Pfizer/BioNTech for up to 40M doses of its #COVID19 vaccine.
We also expect to distribute almost 150M doses of the AstraZeneca/Oxford vaccine in the 1/4 of 2021, once the vaccine is listed for emergency use by @WHO. https://t.co/yx3FFl9bv8— Tedros Adhanom Ghebreyesus (@DrTedros) January 23, 2021
Randomized crossover study shows lower ad libitum energy intake with a plant-based, low-fat diet compared to an animal-based, ketogenic diet
25 Jan, 2021 | 01:25h | UTCCommentary: NIH study compares low-fat, plant-based diet to low-carb, animal-based diet – NIH News Releases
Review: Ambulatory blood pressure monitoring to diagnose and manage hypertension
25 Jan, 2021 | 01:24h | UTCAmbulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension – Hypertension
Global incidence and mortality of neonatal sepsis: A systematic review and meta-analysis
25 Jan, 2021 | 01:22h | UTC
Global variation in postoperative mortality and complications after cancer surgery: a multicenter, prospective cohort study in 82 countries
25 Jan, 2021 | 01:21h | UTCCommentary: Better post-surgical care would boost cancer survival chances – University of Birmingham
Commentary on Twitter (thread – Click for more)
https://twitter.com/ewenharrison/status/1352401851711418372
Meta-analysis: Effect of micronutrient supplements on influenza and other respiratory tract infections among adults
25 Jan, 2021 | 01:17h | UTC
Commentary on Twitter (thread – click for more)
Our new article in @GlobalHealthBMJ suggests that zinc supplementation could almost halve the duration of symptoms of acute respiratory infection in adults. We also found small effects of vitamins C and D supplementation to prevent ARIs. [Thread]https://t.co/aJ4VfYFiBG
— Ibraheem Abioye (@DrAbioye) January 20, 2021
American Clinical Neurophysiology Society’s Standardized Critical Care EEG Terminology: 2021 Version
25 Jan, 2021 | 01:15h | UTC
Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis
25 Jan, 2021 | 01:15h | UTCLong-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)
Machine Learning and the Future of Cardiovascular Care: JACC State-of-the-Art Review
25 Jan, 2021 | 01:08h | UTC
Commentary on Twitter
Our state-of-the-art review on Machine Learning and the Future of Cardiovascular care in @JACCJournals: "Cardiologists must shape how #ML is used in cardiovascular practice" with dr. Arnaout @UCSF (@scrippsresearch @ScrippsRTI #ai) https://t.co/dZYS6QyW12 pic.twitter.com/fLo2UhqocE
— Giorgio Quer (@GiorgioQuer) January 19, 2021
Randomized trial: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer
25 Jan, 2021 | 01:12h | UTCFirst-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC – AJMC
Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
25 Jan, 2021 | 01:13h | UTCFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients
25 Jan, 2021 | 01:43h | UTCStudy Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov
“Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days.”
Commentaries: ‘Major breakthrough’ | Large study shows effectiveness of colchicine to treat COVID-19 – The Canadian AND A gout drug shows promise for Covid-19, but skeptics worry about trusting science by press release – STAT
Commentary on Twitter
Press release 🔥 #colchicine decreased ⬇️
🏥 hospitalizations 25%
🤕 use of ventilation 50%
💀 mortality 44%
in multinational trial of >4,000 non-hospitalized #COVID patientsMore: https://t.co/htMRdParq3
Full report awaited…@EricTopol @DrEricDing @MartinLandray #EBM pic.twitter.com/iodiEJBtV1
— Kari Tikkinen (@KariTikkinen) January 23, 2021
[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
25 Jan, 2021 | 01:42h | UTC
Randomized trial: Bamlanivimab associated with Etesevimab reduce the viral load in patients with mild to moderate COVID-19
25 Jan, 2021 | 01:36h | UTCEditorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19
Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19
25 Jan, 2021 | 01:37h | UTCCommentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine
Commentary on Twitter
NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia
CORIMUNO-ANA-1 trial from Xavier Mariette & colleagueshttps://t.co/SU1Cqmk9MJ pic.twitter.com/gLUkKpKinl
— The Lancet Respiratory Medicine (@LancetRespirMed) January 23, 2021
Revisiting the UK’s strategy for delaying the second dose of the Pfizer covid-19 vaccine
25 Jan, 2021 | 01:32h | UTC
Commentary on Twitter
These new data suggest that the UK govt should reconsider the decision to delay the second dose of the Pfizer/BioNTech vaccine. If they are determined to continue with the delayed second dose, then a robust randomized evaluation is urgently required https://t.co/4xrBFwZWkN
— The BMJ (@bmj_latest) January 24, 2021
Systematic review: At least one third of SARS-CoV-2 infections are asymptomatic
25 Jan, 2021 | 01:33h | UTCCommentary from the authors: The day we let Covid-19 spin out of control – STAT
CDC Report: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine
25 Jan, 2021 | 01:29h | UTCCommentary: CDC reports rare allergic reactions to Moderna’s Covid-19 vaccine – STAT
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
25 Jan, 2021 | 01:35h | UTCOriginal Guideline: COVID-19 rapid guideline: managing the long-term effects of COVID-19 – National Institute for Health and Care Excellence
Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected
25 Jan, 2021 | 01:30h | UTC
Randomized trial: No benefit from corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients
25 Jan, 2021 | 01:28h | UTC
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
25 Jan, 2021 | 01:11h | UTC